|Cell line name||NK-92MIhCD16|
|Resource Identification Initiative||To cite this cell line use: NK-92MIhCD16 (RRID:CVCL_JX95)|
|Comments||Characteristics: Transfected with the CD16-BB-zeta construct that consist of a signal peptide, the FCGR3/CD16A extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD3Z signaling domain.|
Transfected with: HGNC; 3619; FCGR3A (extracellular domain).
Transfected with: HGNC; 6001; IL2.
Caution: NantKwest exclusively owns, controls and distributes NK-92MI. This CD16-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party.
Derived from sampling site: Peripheral blood.
|Disease||Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)|
|Species of origin||Homo sapiens (Human)
(NCBI Taxonomy: 9606)
|Hierarchy||Parent: CVCL_3755 (NK-92MI)|
|Sex of cell||Male|
|Age at sampling||50Y|
|Category||Cancer cell line|
|Last entry updated||07-Sep-2018|